Skip to main content
. 2020 Oct 22;11:584099. doi: 10.3389/fimmu.2020.584099

Figure 1.

Figure 1

The strategies for modifying UCB-derived NK cells include enhancing activation (such as: increase the expression of activating receptor: NKG2D and decrease the expression of inhibitory receptor: NKG2A), targeting tumor antigen and overcoming the immunosuppressive tumor microenvironment (such as IL-6, IL-10, and TGFβ). PEBLs, anti-NKG2A protein expression blockers; CAR, chimeric antigen receptor; UCB, umbilical cord blood; NK cells, natural killer cells.